Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356244 | 0.83 | ADORA2A (0.69) | ADORA2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1355301 | 0.81 | ADORA2A (0.75) | ADORA2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1355300 | 0.78 | ADORA2A (0.70) | ADORA2ANPC1RAB9A | |
| SCHEMBL7678308 | 0.78 | ADORA2A (0.56) | ADORA2ANPC1RAB9A | |
| SCHEMBL1355197 | 0.78 | ADORA2A (0.73) | ADORA2ANPC1RAB9AKDM4E | |
| SCHEMBL1355011 | 0.77 | ADORA2A (1.00) | ADORA2ANPC1RAB9AALDH1A1 | |
| SCHEMBL31365941 | 0.77 | NPC1 (0.69) | ADORA2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1355495 | 0.76 | ADORA2A (0.73) | ADORA2ANPC1RAB9A | |
| SCHEMBL31365955 | 0.75 | NPC1 (0.74) | ADORA2ANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7678306 | 0.75 | ADORA2A (0.52) | ADORA2ANPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |